Results 211 to 220 of about 82,795 (269)

Nicorandil in preventing contrast-induced nephropathy in patients undergoing cardiac catheterization procedures: a systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Waseem R, Kumar A, Kumari S, Kumar S, Bai D, Kumar G, Jabbar M, Ashraf T, Nancy F, Mariam B, Dev S, Turesh M, Yousuf MH, Ejaz U, Jawad S.   +14 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra, B. Botella, M. D. Martín‐Arranz, D. Ceballos, C. Martínez‐Pascual, A. Garrido, P. Varela, M. Moreta, E. Brunet‐Mas, Y. González‐Lama, E. Rodríguez‐González, M. Vicuña, J. P. Gisbert, I. Ordás, F. Argüelles‐Arias, J. Tosca‐Cuquerella, R. Vicente‐Lidón, M. Sierra‐Ausín, I. Rodríguez‐Lago, D. Martín‐Rodríguez, J. M. Paredes, B. Sicilia, I. García de la Filia, N. Jiménez, M. Barreiro‐de Acosta, E. Betoré, I. Ferrer‐Bradley, L. García‐Alles, J. M. Huguet, S. Castellet‐Farrús, M. J. García, A. Gutiérrez‐Casbas, Á. Ponferrada‐Díaz, L. Ramos, M. Calafat, I. Vera, C. Suárez‐Ferrer, E. Fernández‐Velado, S. Rodríguez‐Sánchez, A. Mínguez, A. Mancebo, J. Barrio, S. Lario, D. R. de La Cruz, Alejandro Hernández‐Camba, C. Rodríguez‐Gutiérrez, M. Chaparro, E. Ricart, L. Almenara‐Michelena, A. Balaguer, E. Domènech, P. Nos   +51 more
wiley   +1 more source

Contrast-Induced Nephropathy (CIN) After Invasive Treatment of Acute Coronary Syndromes-Predictors, Short and Long-Term Outcome. [PDF]

J Clin Med
Sielski J, Kaziród-Wolski K, Piotrowska AM, Jurczak B, Klasa A, Kozieł K, Ludew M, Maj F, Merchel L, Pytlak K, Zabojszcz M, Siudak Z.   +11 more
europepmc   +1 more source

Effects of Psyllium Husk on Metabolic Regulators, Insulin Resistance, and SIRT6 in Liver and Muscle of Type 2 Diabetic Rats

Veterinary Medicine and Science, Volume 12, Issue 3, May 2026.
The effects of psyllium husk supplementation on metabolic regulators, insulin resistance markers, and SIRT6 expression in the liver and skeletal muscle tissues of type 2 diabetic rats were investigated. PHP demonstration has significant beneficial effects by partially improving metabolic dysfunctions and increasing antioxidant capacity in T2DM ...
Furkan Ümit, Gülay Çiftci, Burcu Onuk, Recai Aci, Özüm Çaka, Alper Çiftci   +5 more
wiley   +1 more source

The role of carbon dioxide angiography in reducing contrast-induced nephropathy in diabetic foot patients undergoing endovascular treatment. [PDF]

Turk J Med Sci
Uyanik SA, Birgi E, Öztürk S, Asfuroğlu U, Tangobay E, Güven HE.   +5 more
europepmc   +1 more source

Proximal ureteral fibroepithelial polyp with secondary renal atrophy in a dog (Canis lupus familiaris)

Veterinary Record Case Reports, Volume 14, Issue 2, May 2026.
Abstract A 12‐year‐old, male intact, Papillon dog was presented following trauma from a motor vehicle accident. On arrival, the dog was laterally recumbent with neurological dysfunction (modified Glasgow coma scale 12) and multiple injuries, including right hip luxation and suspected haemorrhage.
Charles T. Talbot, Xiaobo Wang, Ji‐Hang Yin   +2 more
wiley   +1 more source

Experimental study of intravoxel incoherent motion diffusion imaging combined with ultrasound renal resistance index in contrast-induced nephropathy. [PDF]

BMC Nephrol
Chen J, Song X, Wang Z, Wang Z.
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Biomarkers in Contrast-Induced Nephropathy: Advances in Early Detection, Risk Assessment, and Prevention Strategies. [PDF]

Int J Mol Sci
Lee PH, Huang SM, Tsai YC, Wang YT, Chew FY.   +4 more
europepmc   +1 more source